Recent Finacing
Recent Raise
Emergence Therapeutics develops antibody‑drug conjugates, advancing ETx‑22—a Nectin‑4‑targeting ADC with tumor‑selective deconjugation and novel linker/payload (amanitin) approaches for multiple solid tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
